|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pectasides D, Pectasides M and
Economopoulos T: Systemic chemotherapy in locally advanced and/or
metastatic bladder cancer. Cancer Treat Rev. 32:456–470. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang CJ, Shen ZJ, Pan CW, Zhong S, Li T
and Zhang MG: Engagement of integrinβ1 induces resistance of
bladder cancer cells to mitomycin-C. Urology. 79:638–643. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Canel M, Serrels A, Frame MC and Brunton
VG: E-cadherin-integrin crosstalk in cancer invasion and
metastasis. J Cell Sci. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Juengel E, dos Santos Meyer S, Schneider
T, Makarevic J, Hudak L, Bartsch G, Haferkamp A, Wiesner C and
Blaheta RA: HDAC inhibition suppresses bladder cancer cell adhesion
to collagen under flow conditions. Exp Biol Med (Maywood).
238:1297–1304. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Danen EH: Integrins: Regulators of tissue
function and cancer progression. Curr Pharm Des. 11:881–891. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamasaki M, Soda S, Sakakibara Y, Suiko M
and Nishiyama K: The importance of 1,2-dithiolane structure in
α-lipoic acid for the downregulation of cell surface β1-integrin
expression of human bladder cancer cells. Biosci Biotechnol
Biochem. 78:1939–1942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Behnsawy HM, Miyake H, Abdalla MA, Sayed
MA, Ahmed Ael-F and Fujisawa M: Expression of integrin proteins in
non-muscle-invasive bladder cancer: Significance of intravesical
recurrence after transurethral resection. BJU Int. 107:240–246.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sharma SV, Haber DA and Settleman J: Cell
line-based platforms to evaluate the therapeutic efficacy of
candidate anticancer agents. Nat Rev Cancer. 10:241–253. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Domingo-Domenech J, Vidal SJ,
Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco
R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J,
et al: Suppression of acquired docetaxel resistance in prostate
cancer through depletion of notch- and hedgehog-dependent
tumor-initiating cells. Cancer Cell. 22:373–388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vallo S, Michaelis M, Rothweiler F,
Bartsch G, Gust KM, Limbart DM, Rödel F, Wezel F, Haferkamp A and
Cinatl J Jr: Drug-resistant urothelial cancer cell lines display
diverse sensitivity profiles to potential second-line therapeutics.
Transl Oncol. 8:210–216. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mani J, Vallo S, Rakel S, Antonietti P,
Gessler F, Blaheta R, Bartsch G, Michaelis M, Cinatl J, Haferkamp A
and Kögel D: Chemoresistance is associated with increased
cytoprotective autophagy and diminished apoptosis in bladder cancer
cells treated with the BH3 mimetic (−)-Gossypol (AT-101). BMC
Cancer. 15:2242015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Michaelis M, Rothweiler F, Barth S, Cinatl
J, van Rikxoort M, Löschmann N, Voges Y, Breitling R, von Deimling
A, Rödel F, et al: Adaptation of cancer cells from different
entities to the MDM2 inhibitor nutlin-3 results in the emergence of
p53-mutated multi-drug resistant cancer cells. Cell Death Dis.
2:e2432011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yilmaz M and Christofori G: Mechanisms of
motility in metastasizing cells. Mol Cancer Res. 8:629–642. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huanwen W, Zhiyong L, Xiaohua S, Xinyu R,
Kai W and Tonghua L: Intrinsic chemoresistance to gemcitabine is
associated with constitutive and laminin-induced phosphorylation of
FAK in pancreatic cancer cell lines. Mol Cancer. 8:1252009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jia Z: Role of integrin-linked kinase in
drug resistance of lung cancer. Onco Targets Ther. 8:1561–1565.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Duxbury MS, Ito H, Benoit E, Waseem T,
Ashley SW and Whang EE: RNA interference demonstrates a novel role
for integrin-linked kinase as a determinant of pancreatic
adenocarcinoma cell gemcitabine chemoresistance. Clin Cancer Res.
11:3433–3438. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miyamoto H, Murakami T, Tsuchida K, Sugino
H, Miyake H and Tashiro S: Tumor-stroma interaction of human
pancreatic cancer: Acquired resistance to anticancer drugs and
proliferation regulation is dependent on extracellular matrix
proteins. Pancreas. 28:38–44. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ploenes T, Scholtes B, Krohn A, Burger M,
Passlick B, Müller-Quernheim J and Zissel G: CC-chemokine ligand 18
induces epithelial to mesenchymal transition in lung cancer A549
cells and elevates the invasive potential. PLoS One. 8:e530682013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lityńska A, Przybyło M, Pocheć E and
Laidler P: Adhesion properties of human bladder cell lines with
extracellular matrix components: The role of integrins and
glycosylation. Acta Biochim Pol. 49:643–650. 2002.PubMed/NCBI
|
|
22
|
Saito T, Kimura M, Kawasaki T, Sato S and
Tomita Y: Correlation between integrin alpha 5 expression and the
malignant phenotype of transitional cell carcinoma. Br J Cancer.
73:327–331. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim SY, Bachman NJ, Nair TS, Goldsmith S,
Liebert M, Grossman HB, Lomax MI and Carey TE: Beta 4 integrin
transfection of UM-UC-2 (human bladder carcinoma) cells: Stable
expression of a spontaneous cytoplasmic truncation mutant with
rapid loss of clones expressing intact beta 4. Cancer Res.
57:38–42. 1997.PubMed/NCBI
|
|
24
|
Harabayashi T, Kanai Y, Yamada T, Sakamoto
M, Ochiai A, Kakizoe T, Koyanagi T and Hirohashi S: Reduction of
integrin beta4 and enhanced migration on laminin in association
with intraepithelial spreading of urinary bladder carcinomas. J
Urol. 161:1364–1371. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chakraborty A, White SM and Guha S:
Granulocyte colony-stimulating receptor promotes
beta1-integrin-mediated adhesion and invasion of bladder cancer
cells. Urology. 68:208–213. 2006. View Article : Google Scholar : PubMed/NCBI
|
